Table 2.

Identification of prognostic survival markers in MB_SHH-Child cohort

	n	Univariate (n=55)		Cross-validated multivariate (n=42)
		HR (95% CI)	p value	HR (95% CI)	p value
MYCN amplification vs no amplification	52	4·47 (1·65–12·1)	0·0032	2·83 (0·87–9·22)	0·084
M+ vs M– disease	55	5·69 (2·01–16·0)	0·0011	4·59 (1·28–16·4)	0·019
TP53 mutation vs no mutation	48	3·47 (1·29–9·30)	0·014	3·44 (1·15–10·2)	0·027
LCA pathology vs non-LCA pathology	52	2·88 (1·15–7·24)	0·025	..	..
TERT wild-type vs TERT mutation	52	2·21 (0·78–6·25)	0·13	..	..
R+ vs R– disease	55	3·45 (1·30–9·19)	0·013	..	..
Male vs female	55	1·13 (0·45–2·82)	0·79	..	..

p values are from Cox proportional hazards analyses. The prognostic significance of covariates selected in cross-validated multivariate models are also shown. HR=hazard ratio. M+=metastatic disease. M–=non-metastatic disease. LCA=large-cell anaplastic. R+=residual disease (subtotal surgical resection). R–=no residual disease (gross total resection).